How does Adaptive Biotechnologies make money?

Adaptive Biotechnologies generates $277M in annual revenue (annual revenue · their business grew +55% last year (GAAP total)).

What is ADPT's XVARY composite score?

Adaptive Biotechnologies (ADPT) has an XVARY composite score of 29/100, rated weak. This combines growth, value, risk, and momentum factors.

ADPT — Adaptive Biotechnologies stock analysis

Start here if you're new

what it is

Adaptive Biotechnologies sells cancer tests that look for leftover disease and runs a drug-discovery business built on immune-system data.

how it gets paid

FY2025 revenue was $277.0M. The MRD segment was $212.3M (~77% of revenue); Immune Medicine was $64.6M (~23%). Totals reflect GAAP reporting (includes Genentech-related revenue recognition in 2025).

why it's growing
Total revenue rose 55% vs. FY2024 (42% if you exclude all Genentech-agreement revenue in both years). MRD revenue grew 46%. The company still posted a GAAP net loss for FY2025.

what just happened

Q4 2025 revenue was $71.7M (+51% vs. Q4 2024). GAAP diluted EPS was $(0.09); the quarter was still loss-making on a GAAP basis.

At a glance

C++ balance sheet — some cracks in the foundation

55/100 earnings predictability — expect surprises

FY2025 positive Adjusted EBITDA (non-GAAP) — still GAAP-loss overall

xvary composite: 29/100 — weak

-$0.25 fy2027 eps est

What they do

Adaptive Biotechnologies sells cancer tests that look for leftover disease and runs a drug-discovery business built on immune-system data.

MRD → minimal residual disease, or tiny bits of cancer left after treatment → so what: doctors pay to watch for relapse. The MRD business is guided to $255M-$265M in 2026 revenue, while the IM business gives you a second engine. Once a hospital validates a test, leaving means new paperwork, retraining, and more lab back-and-forth.

healthcare mid-cap diagnostics biotech drug-discovery

How they make money

$277M annual revenue · their business grew +55% last year (GAAP total)

MRD (minimal residual disease)

$212M

+46%

Immune Medicine

$65M

+93%

The products that matter

minimal residual disease testing

clonoSEQ

$212M · ~77% of FY2025 revenue (MRD segment)

clonoSEQ sits inside the MRD segment: 105,587 tests delivered in FY2025, up 39% vs. 2024. The release also notes the MRD business achieved positive Adjusted EBITDA and positive cash flow for the year.

core

pharma data and services

immune medicine

$65M · ~23% of FY2025 revenue

Immune Medicine revenue was $64.6M in FY2025 (+93% vs. 2024), including revenue recognized as the Genentech agreement fully amortized. Excluding Genentech-related items in both years, Immune Medicine grew 17% — still lumpy, not all recurring.

high growth · lumpy

coverage and workflow expansion

MRD coverage expansion

Medicare added mantle cell lymphoma

the test infrastructure already exists. each added covered indication can push more volume through the same system, which is why new reimbursement decisions matter more than they sound.

volume multiplier

Key numbers

$277M

annual revenue

That is the whole company for FY2025. A $277M business with a -20.6% operating margin is still leaking cash.

~−20.6%

GAAP operating margin (FY2025)

Loss from operations was ~$57.1M on $277.0M revenue — still structurally loss-making on a GAAP operating basis.

$16

VL target

VL’s 18-month target sits 16% below the current $19.12 price. That is a loud vote for patience.

1.75

stock swing

A 1.75 beta means the stock tends to move 75% more than the market. Your ride is rougher than the index.

Financial health

C++

strength

balance sheet grade C++ — below average — limited financial resources
risk rank 5 — safer than 5% of stocks
price stability 5 / 100
GAAP net margin (FY2025) ~−21% — net loss of ~$59.5M on $277.0M revenue
return on equity negative — still burning GAAP earnings while investing in MRD + IM

C++ — net profit margin looks solid but balance sheet grade needs watching.

Total return vs. market

You invested $10,000 in ADPT 3 years ago → it's now worth $20,760.

The index would have given you $14,770.

same period. same starting point. ADPT beat the market by $5,990.

source: institutional data · total return

What just happened

loss narrowed (GAAP)

Q4 2025: $71.7M revenue, GAAP EPS $(0.09) · FY2025 $277.0M total revenue.

Q4 revenue rose 51% vs. the prior-year quarter. FY2025 net loss was $59.5M vs. $159.6M in FY2024. Adjusted EBITDA was $12.2M for FY2025 (non-GAAP).

$71.7M

Q4 2025 revenue

$(0.09)

Q4 GAAP EPS

+55%

FY revenue growth

the number that mattered

FY MRD revenue at $212.3M (+46%) anchors the story; Immune Medicine includes non-recurring Genentech-related recognition in 2025.

adaptive biotechnologies appeared to close out 2025 on a positive note.

in a january 12th press release, the company announced preliminary fourth-quarter figures that were favorable to wall street’s expectations (official results were scheduled to be released just as this issue was going to press).
specifically, leadership indicated that revenues likely came in at $72 million, representing vs. prior year growth of 51% and far exceeding the roughly $60 million that analysts had been targeting on average.

much of the progress was attributable to strength in its cornerstone minimum residual disease (mrd) business, where performance continued to benefit from gains in clinical testing and pharmaceutical activity.
the $72 million total would place adaptive’s full-year revenue tally at about $277 million, representing annual improvement of 55%.

investors should note that this growth rate was inflated by a one-time $34 million gain in the third quarter, stemming from the company’s terminated genentech agreement.
the road map to profitability appears more defined.
adaptive enters 2026 with solid momentum and a generally positive near-term outlook.

snap-source: Adaptive Biotechnologies Q4/FY2025 results (Feb. 5, 2026) — GlobeNewswire via Nasdaq

What could go wrong

the #1 risk is clonoSEQ failing to become standard practice fast enough to justify the valuation.

∘

med

MRD still carries the investment case

clonoSEQ generated $212M of the company's $277M revenue last year. That is 77% concentration in one clinical business line. If test growth slows, most of the bull case slows with it.

impact: the $3B equity story is still tied to one platform and 105,587 annual tests

∘

med

headline growth includes non-repeatable pharma economics

reported revenue grew 55%, but the page data also points to $19.5M in one-time milestones and a separate $34M Genentech termination payment. Those are real dollars, not durable demand. If you value them like recurring revenue, you will overpay.

impact: 2026 revenue is estimated at $275M, slightly below the latest $277M base

∘

med

the balance sheet gives management less room for a stumble

C++ balance sheet grade and a forecast loss of -$0.55 EPS mean the company is better than it was, not self-funding in all scenarios. In a volatile stock with 1.75 beta, missed adoption targets do not get a patient market response.

impact: high volatility plus ongoing losses can turn a slowdown into a sharp multiple reset

$212M of $277M revenue comes from MRD, while recent growth was helped by one-time pharma payments and the company is still expected to lose $0.55 per share next year. That is an improving setup, not a forgiving one.

source: institutional data · regulatory filings · risk analysis

Pay attention to

metric

clonoSEQ test volume

105,587 tests and 39% growth are the proof of adoption. If that growth rate breaks hard, the valuation story breaks with it.

calendar

2026 guidance quality

the key question is whether management can guide beyond the latest $277M base without leaning on another one-off pharma payment.

trend

MRD profitability staying positive

positive EBITDA and cash flow in MRD is the inflection. You want to see that remain true as volumes scale, not disappear after one strong stretch.

risk

pharma revenue normalization

immune medicine grew 90%, but milestone-heavy revenue can reverse just as fast. Watch what happens when the Genentech-related noise clears.

Analyst rankings

short-term outlook

below average

momentum score 4 — in human-speak, analysts think the recent run already priced in a lot of good news.

risk profile

high risk

stability score 5 means real drawdown risk. this is what volatile biotech looks like.

chart momentum

average

technical score 3 says there is no special chart signal here. the business update matters more than the pattern.

earnings predictability

55 / 100

results are harder to model because milestone revenue and biotech timelines rarely move in straight lines.

source: institutional data

Institutional activity

institutions have been net buying for 3 consecutive quarters — 144 buyers vs. 106 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 3 quarters.

source: institutional data · 1q2025-3q2025

source: institutional data

Price targets

3-5 year target range

$6 $25

$19 current price

$16 target midpoint · 16% from current · 3-5yr high: $30 (+55% · 12% ann'l return)

source: institutional data · analyst targets

The deep dive

ADPT

xvary deep dive

adpt

the full analysis is in the works.

what you'll get

dcf valuation model

bull / base / bear scenarios

competitive moat breakdown

quarterly earnings tracker

operating model projections

risk matrix with kill criteria

original price target + conviction

updated with every earnings

free · no spam · you'll be first to read it

adpt

Get this snapshot in your inbox

Want the deeper analysis?